References
- Low TL, Thurman GB, McAdoo M, et al. The chemistry and biology of thymosin. I. Isolation, characterization, and biological activities of thymosin alpha1 and polypeptide beta 1 from calf thymus. J Biol Chem. 1979;254:981–986.
- Naylor PH, Goldstein AL. Thymosin modulates immune and endocrine events. Prog ClinBiol Res. 1988;256:489–502.
- Goldstein AL, Schulof RS, PH N, et al. Thymosins and anti-thymosins: properties and clinical applications. Med Oncol Tumor Pharmacother. 1986;3:211–221.
- Naylor PH, Mutchnick MG. Immunotherapy for hepatitis B in the direct acting antiviral era: reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach. J Viral Hepat. 2017 Oct 20. [Epub ahead of print] Review. DOI:10.1111/jvh.12807
- Hadden JW. Aspects of the immunopharmacology of thymosin α1. Clin Appl Immunol Rev. 2001;1:187–191.
- Sztein MB, Serrate SA. Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J Immunopharmacology. 1989;11:789–800.
- Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling. Blood. 2004;103:4232–4239.
- Krispin A, Bledi Y, Atallah M, et al. Apoptotic cell thrombospondin-1 and heparin-binding domain lead to dendritic-cell phagocytic and tolerizing states. Blood. 2006;108:3580–3589.
- Giuliani C, Napolitano G, Mastino A, et al. Thymosin-α1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol. 2000;30:778–786.
- Baumann CA, Badamchian M, Goldstein AL. Thymosin α1 is a time and dose-dependent antagonist of dexamethasone-induced apoptosis of murine thymocytes in vitro. Int J Immunopharmacol. 2000;22:1057–1066.
- Zhang P, Chan J, Dragoi AM, et al. Activation of IKK by thymosin alpha1 requires the TRAF6 signalling pathway. EMBO Rep. 2005;6:531–537.
- Verastegui E, Barrera JL, Zinser J, et al. A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer. Int J Immunopharmacol. 1997;19:619–627.
- Egan JE, Quadrini KJ, Santiago-Schwarz F, et al. . IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro. J Immunother. 2007;30:624–633.
- Freeman SM, Franco JL, Kenady DE, et al. A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2011;34(2):173–178.
- GT W, Fee WE Jr, RW D, et al. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck. 2011;33:1666–1674.
- Berinstein NL, Wolf GT, Naylor PH, et al. Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother. 2012;61:771–782.
- Naylor PH, Hernandez KE, Nixon AE, et al. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines. Vaccine. 2010;28:7054–7062.
- Berinstein N, Egan JE, Naylor PH. Peptide based vaccine approaches for cancer- a novel approach using a WT1 synthetic long peptide and the IRX2 immunomodulatory regimen. Cancers. 2001;3:3991–4009.
- Hadden JW, Saha SAR, Sosa M, et al. Immunotherapy with natural interleukins and/or Thymosin α1 potently augments T lymphocyte responses of hydrocortisone-treated aged mice. Int J Immunopharmacology. 1995;17:821–828.
- Mastino A, Favalli C, Grelli S, et al. Combination therapy with thymosin α1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int J Cancer. 1992;50:493–499.
- Garaci E, Pica F, Sinibaldi-Vallebona P, et al. Thymosin α1 in combination with cytokines and chemotherapy for the treatment of cancer. Int Immunopharmacol. 2003;3:1145–1150.
- Hadden J, Verastegui E, Barrera JL, et al. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int Immunopharmacology. 2003;3:1073–1081.
- Naylor PH, Quadrini K, Garaci G, et al. Immunopharmacology of Thymosin α1 and cytokine synergy. Ann. N.Y. Acad. Sci. 2007;1112:235–244.
- Naylor PH, Hadden JW. Preclinical Studies with IRX-2 and thymosin alpha 1 in combination therapy. Ann NY Acad Sci. 2010;1194:162–168.
- Hadden JW, Verastegui E,and Hadden E. IRX-2 and Thymosin α1(Zadaxin) increase T lymphocytes in T lymphocytopenic mice and humans. Ann. N.Y. Acad. Sci. 2007;1112:245–255.